AEs leading to trial product discontinuation occurred in 51/603 (8.5%) participants in the CagriSema 2.4 mg/2.4 mg group, 40/605 (6.6%) participants in the semaglutide 2.4 mg group, 7/152 (4.6%) participants in the cagrilintide 2.4 mg group, 42/594 (7.1%) participants in the CagriSema 1 mg/1 mg group, 26/608 (4.3%) participants in the semaglutide 1 mg group, and 2/149 (1.3%) participants in the placebo group
[3] A thorough clinical assessment remains paramount in distinguishing benign from pathological elevations
But NAC supplementation has further use as it has shown to slow down platelet aggregation
Pradeep AR, Ramchandraprasad MV, Bajaj P, Rao NS, Agarwal E
Individual results may vary, and consultation with licensed healthcare providers is recommended before beginning any injectable therapy protocol
This method of injection is only applicable for administering a small dose of drugs